Price$90.48+0.92 (+1.03%)
01:30 PM07:45 PM
News · 26 weeks96+25%
2025-12-282026-06-21
Mix4390d
- Insider21(49%)
- Other12(28%)
- SEC Filings6(14%)
- Earnings2(5%)
- Analyst1(2%)
- Dividends1(2%)
Latest news
25 items- INSIDERDirector Stratton John G bought $173,640 worth of Common shares without par value (2,000 units at $86.82), increasing direct ownership by 9% to 23,319 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- SECSEC Form 11-K filed by Abbott Laboratories11-K - ABBOTT LABORATORIES (0000001800) (Filer)
- PRAbbott declares 410th consecutive quarterly dividendABBOTT PARK, Ill., June 12, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE:ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 410th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 17, 2026, to shareholders of record at the close of business on July 15, 2026.Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of
- PRNew research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workersStudy at ADA's Scientific Sessions shows participants in Abbott's Healthy Food Rx program combined with health coaching had significant health improvementsAbbott's Healthy Food Rx program is a Food is Medicine initiative delivering recipe-based food boxes and nutrition education to people living with diabetesNEW ORLEANS, June 8, 2026 /PRNewswire/ -- New research presented at the American Diabetes Association's 86th Scientific Sessions showed that adults living with type 2 diabetes participating in Abbott's (NYSE:ABT) Healthy Food Rx "Food is Medicine" program, paired with community health worker–led coaching, experienced major improvements in healthy eating, physical activity, diabetes self-
- PRNew Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosisDiabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect earlyKetone monitoring is not yet routine in diabetes care, which may contribute to missed warning signs of DKA and delays in interventionNearly 60% of pediatric hospitalizations for Type 1 diabetes in the U.S. are associated with DKA1ABBOTT PARK, Ill., June 6, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected health concern for people living with both Type 1 and Type 2 diabetes. Findings from multiple Abbott studies shared at the American Diabetes Association's (ADA) June 2026 86th Scientific
- SECSEC Form SD filed by Abbott LaboratoriesSD - ABBOTT LABORATORIES (0000001800) (Filer)
- PRAbbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetesFirst-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabetic ketoacidosis, a serious health condition for people with diabetesIntegrates with the Libre digital health ecosystem, allowing people to share glucose and ketone data with caregivers and healthcare providersDesigned for compatibility with leading automated insulin delivery (AID) systemsABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose‑ketone sensing technology for people with
- PRACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screeningCologuard® and Cologuard Plus® reaffirmed as preferred options for noninvasive colorectal cancer (CRC) screening in updated American Cancer Society guidelineAbbott to offer only CRC screening portfolio aligned to new ACS recommendations combining preferred stool-based plus additional blood-based optionsRecent publications support Cologuard-first strategy, demonstrating better outcomes for patients, providers, health systems, and payersABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the American Cancer Society (ACS) has released updated colorectal cancer (CRC) screening guidelines that reaffirm Cologuard® and Cologuard Plus® as preferred noninvasive scr
- PRAbbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remissionNew MRD data from the PARTNER study demonstrate enhanced sensitivity in early triple-negative breast cancerEarly MCED prospective data show low anxiety and minimal psychological burden in real-world useABBOTT PARK, Ill., May 26, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will present 11 abstracts featuring new evidence across the cancer care continuum at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago. The presentations showcase the breadth of Abbott's integrated cancer diagnost
- INSIDERSEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Abbott LaboratoriesSCHEDULE 13G - ABBOTT LABORATORIES (0000001800) (Subject)
- SECSEC Form 10-Q filed by Abbott Laboratories10-Q - ABBOTT LABORATORIES (0000001800) (Filer)
- INSIDERDirector Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERNew insider Conroy Kevin T claimed ownership of 131,451 units of Common shares without par value (SEC Form 3)3 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Stratton John G was granted 2,286 units of Common shares without par value, increasing direct ownership by 12% to 21,319 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Starks Daniel J bought $926,537 worth of Common shares without par value (10,000 units at $92.65) and was granted 2,286 units of Common shares without par value, increasing direct ownership by 0.18% to 6,751,103 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Roman Michael F was granted 2,286 units of Common shares without par value, increasing direct ownership by 27% to 10,764 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector O'Grady Michael was granted 2,286 units of Common shares without par value, increasing direct ownership by 43% to 7,603 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Mckinstry Nancy was granted 2,286 units of Common shares without par value, increasing direct ownership by 6% to 41,010 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Mcdew Darren W was granted 2,286 units of Common shares without par value, increasing direct ownership by 22% to 12,678 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Kumbier Michelle was granted 2,286 units of Common shares without par value, increasing direct ownership by 15% to 18,000 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Gonzalez Patricia Paola was granted 2,286 units of Common shares without par value, increasing direct ownership by 33% to 9,205 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Blount Sally E. was granted 2,286 units of Common shares without par value, increasing direct ownership by 7% to 36,344 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Babineaux-Fontenot Claire was granted 2,286 units of Common shares without par value, increasing direct ownership by 43% to 7,603 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Ahuja Nita was granted 2,286 units of Common shares without par value (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
ABT FAQ
7 questionsWhat does Abbott Laboratories do?
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo...Where does ABT stock trade?
Abbott Laboratories (ABT) is listed on NYSE.What sector and industry is ABT in?
Abbott Laboratories operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does ABT pay a dividend?
Yes. ABT's next ex-dividend date is 2026-07-15 with a declared cash dividend of $0.63 per share, payable 2026-08-17.What are analysts saying about ABT?
Abbott Laboratories has had 8 recent analyst actions on file. The most recent action was from Daiwa Securities: Neutral on 2026-04-22.What companies are similar to ABT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ABT side-by-side with any of them on Quantisnow.How can I track ABT on Quantisnow?
Quantisnow aggregates Abbott Laboratories's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABT to receive live email and push alerts on every new disclosure.